![AACR 2017 | Poster 4295/4 – AZ'5576 demonstrates in vitro and in vivo activity in preclinical models of ABC Diffuse Large B-Cell Lymphoma AACR 2017 | Poster 4295/4 – AZ'5576 demonstrates in vitro and in vivo activity in preclinical models of ABC Diffuse Large B-Cell Lymphoma](https://lymphomahub.com/media/images/29/1a/thumb-3412-pagebody-body2x.jpeg)
AACR 2017 | Poster 4295/4 – AZ'5576 demonstrates in vitro and in vivo activity in preclinical models of ABC Diffuse Large B-Cell Lymphoma
![AACR 2017 | Poster CT132/13 – A phase IIb randomized study (SADAL) of selinexor achieves durable responses in GCB & Non-GCB subtypes of relapsed/refractory Diffuse Large B-Cell Lymphoma AACR 2017 | Poster CT132/13 – A phase IIb randomized study (SADAL) of selinexor achieves durable responses in GCB & Non-GCB subtypes of relapsed/refractory Diffuse Large B-Cell Lymphoma](https://lymphomahub.com/media/images/d5/c7/thumb-3427-pagebody-body2x.jpeg)
AACR 2017 | Poster CT132/13 – A phase IIb randomized study (SADAL) of selinexor achieves durable responses in GCB & Non-GCB subtypes of relapsed/refractory Diffuse Large B-Cell Lymphoma
![AACR 2017 | Poster 3939/6 – two evolutionary models proposed for development of drug resistance between primary and relapsed Diffuse Large B-Cell Lymphoma AACR 2017 | Poster 3939/6 – two evolutionary models proposed for development of drug resistance between primary and relapsed Diffuse Large B-Cell Lymphoma](https://lymphomahub.com/media/images/94/8d/thumb-3395-pagebody-body2x.jpeg)
AACR 2017 | Poster 3939/6 – two evolutionary models proposed for development of drug resistance between primary and relapsed Diffuse Large B-Cell Lymphoma
![AACR 2017 | Poster 2033/5 – Testing the combined effects of low dose olaparib plus ibrutinib on Mantle Cell Lymphoma cytotoxicity AACR 2017 | Poster 2033/5 – Testing the combined effects of low dose olaparib plus ibrutinib on Mantle Cell Lymphoma cytotoxicity](https://lymphomahub.com/media/images/4c/2f/thumb-3387-pagebody-body2x.jpeg)
AACR 2017 | Poster 2033/5 – Testing the combined effects of low dose olaparib plus ibrutinib on Mantle Cell Lymphoma cytotoxicity
![Evaluation of ETS2101 in Combination with anti-mCTLA4 Monoclonal Antibody on CD4 and CD8 TILs in a Subcutaneous CT-26 Colorectal Cancer Model - OracleBio Evaluation of ETS2101 in Combination with anti-mCTLA4 Monoclonal Antibody on CD4 and CD8 TILs in a Subcutaneous CT-26 Colorectal Cancer Model - OracleBio](https://oraclebio.com/wp-content/uploads/2020/08/E-therapeutics_OracleBio-poster_AACR2017_DPH1_VF_3_vf-scaled.jpg)
Evaluation of ETS2101 in Combination with anti-mCTLA4 Monoclonal Antibody on CD4 and CD8 TILs in a Subcutaneous CT-26 Colorectal Cancer Model - OracleBio
![Mike Caligiuri Discusses Upcoming AACR Meeting, Cancer Health Equality, and Sudden Career Change - Onco'Zine Mike Caligiuri Discusses Upcoming AACR Meeting, Cancer Health Equality, and Sudden Career Change - Onco'Zine](https://www.oncozine.com/wp-content/uploads/2017/07/AACR-2017-2.jpg)
Mike Caligiuri Discusses Upcoming AACR Meeting, Cancer Health Equality, and Sudden Career Change - Onco'Zine
![Poster #5915: Three-dimensional (3-D) Multiplex Imaging of Biomarkers in Tumor Tissue - ClearLight Biotechnologies Poster #5915: Three-dimensional (3-D) Multiplex Imaging of Biomarkers in Tumor Tissue - ClearLight Biotechnologies](https://clearlightbiotechnologies.com/wp-content/uploads/2018/09/AACR-2017-poster-scaled.jpg)
Poster #5915: Three-dimensional (3-D) Multiplex Imaging of Biomarkers in Tumor Tissue - ClearLight Biotechnologies
![Utilizing multiplex chromogenic IHC and digital image analysis to evaluate immune cell content and spatial distribution within NSCLC tumor tissue - OracleBio Utilizing multiplex chromogenic IHC and digital image analysis to evaluate immune cell content and spatial distribution within NSCLC tumor tissue - OracleBio](https://oraclebio.com/wp-content/uploads/2020/08/Asterand_OracleBio-poster_AACR2017_final-scaled.jpg)
Utilizing multiplex chromogenic IHC and digital image analysis to evaluate immune cell content and spatial distribution within NSCLC tumor tissue - OracleBio
![AACR 2017: Allosteric inhibition of the Receptor Tyrosine Kinases c-MET, RON and VEGFR-2 via the co-receptor CD44v6 by the novel compound AMC303 – amcure AACR 2017: Allosteric inhibition of the Receptor Tyrosine Kinases c-MET, RON and VEGFR-2 via the co-receptor CD44v6 by the novel compound AMC303 – amcure](https://amcure.com/wp-content/uploads/2019/06/AACR-Poster-4911.jpg)